{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:33:57Z","timestamp":1762079637261,"version":"3.41.0"},"reference-count":3,"publisher":"Gobierno de Navarra","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2018,8,29]]},"DOI":"10.23938\/assn.0297","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T10:42:50Z","timestamp":1530009770000},"page":"277-278","source":"Crossref","is-referenced-by-count":4,"title":["Lethal interaction between 5-fluorouracil and brivudine"],"prefix":"10.23938","volume":"41","member":"10024","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: a review of recent observational studies","volume":"38","author":"BOUVY","year":"2015","unstructured":"1. BOUVY JC, DE BRUIN ML, KOOPMANSCHAP MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf 2015; 38:437-453.","journal-title":"Drug Saf"},{"key":"ref1","unstructured":"2. AGENCIA ESPA\u00d1OLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS (AEMPS). Brivudina (Nervinex): se recuerda que est\u00e1 contraindicada su administraci\u00f3n junto con antineopl\u00e1sicos, especialmente 5-fluoropirimidinas debido a la interacci\u00f3n potencialmente mortal. Nota informativa. MUH (FV), 9\/2017. Disponible en https:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2017\/docs\/NI-MUH_FV_09-2017-brivudina-Nervinex.pdf"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/02841860802660502","article-title":"Fatal drug-drug interaction of brivudine and capecitabine","volume":"48","author":"R\u00c4TZ BRAVO","year":"2009","unstructured":"3. R\u00c4TZ BRAVO AE, HOFER S, KR\u00c4HENB\u00dcHL S, LUDWIG C. Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol 2009; 48: 631-633.","journal-title":"Acta Oncol"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/63982\/40725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:37:52Z","timestamp":1749551872000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/63982\/40725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":3,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0297","relation":{},"ISSN":["1137-6627"],"issn-type":[{"type":"print","value":"1137-6627"}],"subject":[],"published":{"date-parts":[[2018,8,29]]}}}